OBJECTIVE: It is still not clear how advances in the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) have impacted long-term outcomes. We undertook this study to examine changes over 25 years in long-term clinical outcomes, including the impact of renal function at diagnosis (a potential marker of time to disease detection) and the duration of cyclophosphamide use in AAV patients with renal involvement. METHODS: We included ANCA-positive patients with biopsy-proven AAV diagnosed between 1985 and 2009 who were followed up in the Glomerular Disease Collaborative Network inception cohort. Outcomes included the composite outcome of end-stage renal disease (ESRD) or death as well as relapse. Cox proportional hazards or competing risks regression models were adjusted for potential baseline confounders. RESULTS: Data from 554 patients were included in the analysis. There was a decreasing 5-year risk of ESRD or death over time (P < 0.001 by log rank test for trend). After adjustment for baseline characteristics, the risk of relapse was similar across the time periods (P = 0.45 by test for trend). Serum creatinine level at baseline was the only significant predictor of an increased risk of ESRD or death (hazard ratio 1.11 per 1 mg/dl of serum creatinine [95% confidence interval 1.04-1.18], P = 0.002). CONCLUSION: In patients with renal disease secondary to AAV, over 25 years the risk of ESRD or death has decreased but the risk of relapse has not changed. A higher serum creatinine level at diagnosis is associated with a higher risk of ESRD or death, suggesting that earlier disease detection is potentially an important measure to improve outcomes in AAV.
OBJECTIVE: It is still not clear how advances in the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) have impacted long-term outcomes. We undertook this study to examine changes over 25 years in long-term clinical outcomes, including the impact of renal function at diagnosis (a potential marker of time to disease detection) and the duration of cyclophosphamide use in AAVpatients with renal involvement. METHODS: We included ANCA-positive patients with biopsy-proven AAV diagnosed between 1985 and 2009 who were followed up in the Glomerular Disease Collaborative Network inception cohort. Outcomes included the composite outcome of end-stage renal disease (ESRD) or death as well as relapse. Cox proportional hazards or competing risks regression models were adjusted for potential baseline confounders. RESULTS: Data from 554 patients were included in the analysis. There was a decreasing 5-year risk of ESRD or death over time (P < 0.001 by log rank test for trend). After adjustment for baseline characteristics, the risk of relapse was similar across the time periods (P = 0.45 by test for trend). Serum creatinine level at baseline was the only significant predictor of an increased risk of ESRD or death (hazard ratio 1.11 per 1 mg/dl of serum creatinine [95% confidence interval 1.04-1.18], P = 0.002). CONCLUSION: In patients with renal disease secondary to AAV, over 25 years the risk of ESRD or death has decreased but the risk of relapse has not changed. A higher serum creatinine level at diagnosis is associated with a higher risk of ESRD or death, suggesting that earlier disease detection is potentially an important measure to improve outcomes in AAV.
Authors: Michael Walsh; Oliver Flossmann; Annelies Berden; Kerstin Westman; Peter Höglund; Coen Stegeman; David Jayne Journal: Arthritis Rheum Date: 2012-02
Authors: Robert A F de Lind van Wijngaarden; Herbert A Hauer; Ron Wolterbeek; David R W Jayne; Gill Gaskin; Niels Rasmussen; Laure-Hélène Noël; Franco Ferrario; Rüdiger Waldherr; E Christiaan Hagen; Jan A Bruijn; Ingeborg M Bajema Journal: J Am Soc Nephrol Date: 2006-07-06 Impact factor: 10.121
Authors: JulieAnne G McGregor; Susan L Hogan; Yichun Hu; Caroline E Jennette; Ronald J Falk; Patrick H Nachman Journal: Clin J Am Soc Nephrol Date: 2011-12-01 Impact factor: 8.237
Authors: Lorraine Harper; Matthew D Morgan; Michael Walsh; Peter Hoglund; Kerstin Westman; Oliver Flossmann; Vladimir Tesar; Phillipe Vanhille; Kirsten de Groot; Raashid Luqmani; Luis Felipe Flores-Suarez; Richard Watts; Charles Pusey; Annette Bruchfeld; Niels Rasmussen; Daniel Blockmans; Caroline O Savage; David Jayne Journal: Ann Rheum Dis Date: 2011-11-29 Impact factor: 19.103
Authors: Anthony D Booth; Mike K Almond; Aine Burns; Peter Ellis; Gill Gaskin; Guy H Neild; Martin Plaisance; Charles D Pusey; David R W Jayne Journal: Am J Kidney Dis Date: 2003-04 Impact factor: 8.860
Authors: Neil Basu; Andrew McClean; Lorraine Harper; Esther Nicole Amft; Neeraj Dhaun; Raashid A Luqmani; Mark A Little; David Rw Jayne; Oliver Flossmann; John McLaren; Vinod Kumar; Lars P Erwig; David M Reid; Gareth T Jones; Gary J Macfarlane Journal: Ann Rheum Dis Date: 2013-01-25 Impact factor: 19.103
Authors: E M Miloslavsky; U Specks; P A Merkel; P Seo; R Spiera; C A Langford; G S Hoffman; C G M Kallenberg; E W St Clair; N K Tchao; L Viviano; L Ding; L P Sejismundo; K Mieras; D Iklé; B Jepson; M Mueller; P Brunetta; N B Allen; F C Fervenza; D Geetha; K Keogh; E Y Kissin; P A Monach; T Peikert; C Stegeman; S R Ytterberg; J H Stone Journal: Arthritis Rheum Date: 2013-09
Authors: Marta Casal Moura; Maria V Irazabal; Alfonso Eirin; Ladan Zand; Sanjeev Sethi; Bijan J Borah; Jeffrey L Winters; James P Moriarty; Rodrigo Cartin-Ceba; Alvise Berti; Misbah Baqir; Gwen E Thompson; Ashima Makol; Kenneth J Warrington; Viengneesee Thao; Ulrich Specks; Fernando C Fervenza Journal: J Am Soc Nephrol Date: 2020-08-21 Impact factor: 10.121
Authors: Jan Henrik Schirmer; Peer M Aries; Kirsten de Groot; Bernhard Hellmich; Julia U Holle; Christian Kneitz; Ina Kötter; Peter Lamprecht; Ulf Müller-Ladner; Eva Reinhold-Keller; Christof Specker; Michael Zänker; Frank Moosig Journal: Z Rheumatol Date: 2017-11 Impact factor: 1.372
Authors: Lillian Barra; Renée L Borchin; Cristina Burroughs; George C Casey; Carol A McAlear; Antoine G Sreih; Kalen Young; Peter A Merkel; Christian Pagnoux Journal: Clin Exp Rheumatol Date: 2018-01-10 Impact factor: 4.473
Authors: Joanna C Robson; Jill Dawson; Helen Doll; Peter F Cronholm; Nataliya Milman; Katherine Kellom; Susan Ashdown; Ebony Easley; Don Gebhart; Georgia Lanier; John Mills; Jacqueline Peck; Raashid Ahmed Luqmani; Judy Shea; Gunnar Tomasson; Peter A Merkel Journal: Ann Rheum Dis Date: 2018-04-25 Impact factor: 19.103
Authors: Jennifer Scott; Carolina Canepa; Antonia Buettner; Louise Ryan; Bróna Moloney; Sarah Cormican; Cathal Walsh; Arthur White; Alan D Salama; Mark A Little Journal: Sci Rep Date: 2021-06-22 Impact factor: 4.379